About
Metagenomi Therapeutics
MGX.US
Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company’s lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc.
Profile
- Company Name
- Metagenomi Therapeutics, Inc.
- Market
- NasdaqGS
- Founded
- Industry
- --
- Fiscal Year End
- December 31
- Website
- metagenomi.co